Akebia Therapeutics Inc (AKBA)

$1.44

-0.04

(-2.7%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.41
    $1.50
    $1.44
    downward going graph

    1.91%

    Downside

    Day's Volatility :5.83%

    Upside

    4.0%

    downward going graph
  • $0.78
    $2.48
    $1.44
    downward going graph

    45.83%

    Downside

    52 Weeks Volatility :68.54%

    Upside

    41.94%

    downward going graph

Returns

PeriodAkebia Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
10.45%
6.5%
0.0%
6 Months
-8.64%
7.1%
0.0%
1 Year
2.07%
9.8%
0.0%
3 Years
-40.08%
14.2%
-20.2%

Highlights

Market Capitalization
308.1M
Book Value
- $0.13
Earnings Per Share (EPS)
-0.22
PEG Ratio
0.0
Wall Street Target Price
5.0
Profit Margin
-22.99%
Operating Margin TTM
-43.82%
Return On Assets TTM
-8.37%
Return On Equity TTM
-553.45%
Revenue TTM
187.2M
Revenue Per Share TTM
0.97
Quarterly Revenue Growth YOY
-18.5%
Gross Profit TTM
140.0M
EBITDA
4.0M
Diluted Eps TTM
-0.22
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.26
EPS Estimate Next Year
-0.33
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Akebia Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 247.22%

Current $1.44
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Akebia Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akebia Therapeutics Inc
Akebia Therapeutics Inc
60.05%
-8.64%
2.07%
-40.08%
-61.95%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akebia Therapeutics Inc
Akebia Therapeutics Inc
NA
NA
0.0
-0.26
-5.53
-0.08
NA
-0.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akebia Therapeutics Inc
Akebia Therapeutics Inc
Buy
$308.1M
-61.95%
NA
-22.99%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Akebia Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 56.19M → 32.60M (in $), with an average decrease of 42.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 614.0K → -17.98M (in $), with an average decrease of 3029.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 59.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 226.6%

Institutional Holdings

  • SATTER MANAGEMENT CO., L.P.

    6.30%

  • Vanguard Group Inc

    3.92%

  • Acadian Asset Management LLC

    2.53%

  • Renaissance Technologies Corp

    1.74%

  • Millennium Management LLC

    1.56%

  • BlackRock Inc

    1.21%

Company Information

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Organization
Akebia Therapeutics Inc
Employees
167
CEO
Mr. John P. Butler MBA
Industry
Health Technology

Discover More

FAQs